This case highlights the potential synergy of combining the inhibition of angiogenesis, immune modulation, and mTOR suppression, contributing to the evolving landscape of RCC combination therapies and suggesting avenues for multi-pathway research. Here, MTOR is linked to renal cell carcinoma.